Last Patient Last Visit (LPLV) reached in the SAPHIR Study
April 07, 2017 02:22 ET
|
Probiodrug
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Last Patient Last Visit (LPLV) reached...
Probiodrug to attend International Conferences in April 2017
April 03, 2017 01:00 ET
|
Probiodrug
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Probiodrug to attend International...
Probiodrug reports full year 2016 financial results
March 30, 2017 01:00 ET
|
Probiodrug
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Probiodrug reports full year 2016...
Probiodrug to present at Alzheimer's and Parkinson's Diseases Congress
March 28, 2017 01:00 ET
|
Probiodrug
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Probiodrug to present at...
Probiodrug AG to Publish its Full Year 2016 Results on 30 March 2017
March 23, 2017 02:00 ET
|
Probiodrug
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Probiodrug AG to Publish its Full...
Probiodrug to attend and present at International Conferences in March 2017
March 06, 2017 01:00 ET
|
Probiodrug
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Probiodrug to attend and present at...
Probiodrug to attend and present at International Conferences in February 2017
February 02, 2017 01:00 ET
|
Probiodrug
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Probiodrug to attend and present at...
Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer's disease patients
January 09, 2017 01:00 ET
|
Probiodrug
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Probiodrug announces completion of...
Probiodrug to attend International Conferences in January 2017
January 04, 2017 01:00 ET
|
Probiodrug
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Probiodrug to attend International...
Probiodrug: Innovative Phase II study design of Glutaminylcyclase Inhibitor PQ912 in early Alzheimer's disease
December 08, 2016 01:00 ET
|
Probiodrug
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Innovative Phase II study design of...